Contribution of infliximab population pharmacokinetic model for dose optimization in ulcerative colitis patients

Rev Esp Enferm Dig. 2016 Feb;108(2):104-5.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • Colitis, Ulcerative / drug therapy*
  • Gastrointestinal Agents / therapeutic use
  • Humans
  • Infliximab*
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Gastrointestinal Agents
  • Infliximab